Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Takeda Kampo Ichoyaku A-matsu is a traditional Japanese Kampo medicine (herbal medicine) based on the Anchusan formulation. It was developed by Takeda Pharmaceutical Company and is currently marketed by Alinamin Pharmaceutical. Presented as fine granules, it is specifically indicated for individuals with moderate or slightly weak physical strength who suffer from nervous gastritis, chronic gastritis, and general gastrointestinal weakness. The formulation works to improve the function of a weakened stomach and alleviate symptoms such as stomachache, abdominal pain, heartburn, belching, loss of appetite, and nausea. It is typically administered orally before or between meals.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Takeda Kampo Ichoyaku A-matsu.